Dear Pharmaceutical Professional,

The non-Hodgkin lymphoma (NHL) market will be impacted by data presented during the virtual American Society of Hematology (ASH) meeting. With this year’s new virtual format, do you have a strategy for understanding the commercial impact of breaking data in NHL?

As seasoned experts in bringing congress data to hematologists/oncologists in their practice, our team will be working with 30 hem/oncs during the meeting to better understand the commercial implications of data presented for:

    polatuzumab vedotin + bendamustine + rituximab
    polatuzumab vedotin
    odronextamab (REGN1979)
    mosunetuzumab (Mosun)
    epcoritamab
    VIPOR (venetoclax + ibrutinib + prednisone + obinutuzumab + lenalidomide)
    polatuzumab vedotin + venetoclax + rituximab
    loncastuximab tesirine (ADCT-402)
    loncastuximab tesirine (ADCT-402) + ibrutinib
    tafasitamab (MOR208) + lenalidomide

Order your 60-slide report so you can make better decisions today and prepare for tomorrow.

Sincerely,

The Breaking Data Team

Non-Hodgkin Lymphoma ASH 2020

American Society of Hematology

Virtual Meeting
December 5 to December 8

Share:

Stay Connected with Hem/Oncs at ASH 2020

Learn More